文献速递骨软组织肉瘤与黑色素瘤

帕唑帕尼治疗晚期骨外黏液样软骨肉瘤:多中心单臂二期试验

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-07-19

这项单臂开放标签二期试验在西班牙、意大利和法国11个中心纳入26例NR4A3易位晚期骨外黏液样软骨肉瘤患者,接受帕唑帕尼800 mg/日口服。改良意向治疗人群23例中22例可评估,4例(18%[95%CI 1-36])达RECIST客观缓解,无死亡或4级不良事件。帕唑帕尼在该病中显示有临床意义的抗肿瘤活性。

要点

  • 帕唑帕尼在晚期骨外黏液样软骨肉瘤中客观缓解率为18%(95%CI 1-36)。
  • 最常见3级不良事件为高血压(35%)、ALT升高(23%)、AST升高(19%)。
  • 未发生死亡或4级不良事件,安全性总体可控。

核心结论

  • 帕唑帕尼在进展期晚期骨外黏液样软骨肉瘤患者中具有临床意义的抗肿瘤活性。
  • 帕唑帕尼可考虑作为一线蒽环类化疗失败后的治疗选择。

研究设计与样本

  • 单臂、开放标签二期试验,预设三个平行独立队列分别报告,本文报告骨外黏液样软骨肉瘤队列。
  • 在西班牙、意大利和法国肉瘤协作组的11个研究站点入组患者。
  • 纳入年龄≥18岁、NR4A3易位、转移性或不可切除、近6个月内RECIST进展、ECOG体力状态0-2的骨外黏液样软骨肉瘤患者。
  • 患者持续口服帕唑帕尼800 mg/日,直至疾病进展、不可接受毒性、死亡、不依从、患者拒绝或研究者决定。

主要发现

  • 2014年6月24日至2017年1月17日,26例患者入组并开始帕唑帕尼治疗,其中23例符合改良意向治疗分析标准。
  • 中位随访27个月(IQR 18-30)。
  • 22例可评估主要终点(1例在主要分析前死亡),4例(18%[95%CI 1-36])达到RECIST客观缓解。
  • 未发生死亡或4级不良事件。
  • 最常见的3级不良事件为高血压(26例中9例[35%])、丙氨酸氨基转移酶升高(6例[23%])和天冬氨酸氨基转移酶升高(5例[19%])。

关键数值与推荐

  • 客观缓解率18%(95%CI 1-36),基于改良意向治疗人群中22例可评估患者。
  • 3级高血压发生率35%(9/26),3级ALT升高23%(6/26),3级AST升高19%(5/26)。

临床怎么用

  • 对于一线蒽环类化疗失败的进展期晚期骨外黏液样软骨肉瘤患者,帕唑帕尼可作为候选治疗选择。
  • 治疗期间需重点监测血压和肝功能,警惕3级高血压及转氨酶升高。

局限性

  • 单臂设计,无随机对照,样本量小(26例入组,22例可评估主要终点)。
  • 预设三个平行队列分别报告,本文仅报告骨外黏液样软骨肉瘤队列结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extraskeletal myxoid chondrosarcoma is a rare sarcoma with low sensitivity to cytotoxic chemotherapy. Retrospective evidence suggests that antiangiogenic drugs could be a treatment option. We aimed to investigate the activity of pazopanib, an antiangiogenic drug, in patients with advanced extraskeletal myxoid chondrosarcoma. METHODS: In this single-arm, open-label phase 2 trial, three parallel independent cohorts of different histotypes of advanced sarcomas were recruited (extraskeletal myxoid chondrosarcoma, typical solitary fibrous tumour, and malignant-dedifferentiated solitary fibrous tumour). In each cohort, patients received pazopanib. In this Article, we report the results of the cohort of patients with advanced extraskeletal myxoid chondrosarcoma. Separate reporting of the three cohorts was prespecified in the study protocol. In this cohort, adult patients (aged ≥18 years) with a diagnosis of NR4A3-translocated, metastatic, or unresectable extraskeletal myxoid chondrosarcoma, who had Response Evaluation Criteria in Solid Tumors (RECIST) progression in the previous 6 months, and had an Eastern Cooperative Oncology Group performance status of 0-2, were enrolled at 11 study sites of the Spanish, Italian, and French sarcoma groups. Patients received oral pazopanib (800 mg/day) continuously, until disease progression, unacceptable toxicity, death, non-compliance, patient refusal, or investigator's decision. The primary endpoint was the proportion of patients achieving an objective response according to RECIST 1·1 in the modified intention-to-treat population (patients who provided consent and had a central molecularly confirmed diagnosis of extraskeletal myxoid chondrosarcoma). The safety analysis included all patients who received at least one dose of pazopanib. This study is registered with ClinicalTrials.gov, number NCT02066285. FINDINGS: Between June 24, 2014, and Jan 17, 2017, 26 patients entered the study and started pazopanib. Of these, 23 met the eligibility criteria for the modified intention-to-treat analysis. Median follow-up was 27 months (IQR 18-30). 22 patients (one patient died before the primary analysis) were evaluable for the primary endpoint: four (18% [95% CI 1-36]) had a RECIST objective response. No deaths or grade 4 adverse events occurred. The most frequent grade 3 adverse events were hypertension (nine [35%] of 26 patients), increased concentration of alanine aminotransferase (six [23%]), and increased aspartate aminotransferase (five [19%]). INTERPRETATION: Pazopanib had clinically meaningful antitumour activity in patients with progressive and advanced extraskeletal myxoid chondrosarcoma, and could be considered a suitable option after failure to respond to first-line anthracycline-based chemotherapy in these patients. FUNDING: Spanish Group for Research on Sarcomas, Italian Sarcoma Group, French Sarcoma Group, GlaxoSmithKline, and Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Stacchiotti S, Ferrari S, Redondo A, et al. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019. PMID: 31331701. doi:10.1016/S1470-2045(19)30319-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。